Zacks: Analysts Anticipate Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Will Post Quarterly Sales of $3.43 Million

Equities research analysts predict that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will announce sales of $3.43 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Protagonist Therapeutics’ earnings. The lowest sales estimate is $2.30 million and the highest is $5.00 million. Protagonist Therapeutics reported sales of $13.11 million during the same quarter last year, which indicates a negative year over year growth rate of 73.8%. The business is scheduled to issue its next earnings report on Wednesday, November 3rd.

According to Zacks, analysts expect that Protagonist Therapeutics will report full year sales of $13.82 million for the current financial year, with estimates ranging from $8.45 million to $18.95 million. For the next fiscal year, analysts anticipate that the business will report sales of $43.82 million, with estimates ranging from $9.10 million to $75.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Wednesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.14). The company had revenue of $2.27 million during the quarter, compared to analyst estimates of $5.60 million. Protagonist Therapeutics had a negative net margin of 299.39% and a negative return on equity of 30.58%.

PTGX has been the topic of a number of recent analyst reports. Zacks Investment Research cut Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 11th. SVB Leerink lifted their price objective on Protagonist Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, August 5th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target (down from $60.00) on shares of Protagonist Therapeutics in a research note on Monday, September 20th. JPMorgan Chase & Co. lowered Protagonist Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $60.00 to $49.00 in a research note on Monday, September 20th. Finally, Piper Sandler boosted their price target on Protagonist Therapeutics from $53.00 to $93.00 and gave the company an “overweight” rating in a research note on Friday, July 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $51.63.

In other Protagonist Therapeutics news, insider David Y. Liu sold 14,779 shares of the firm’s stock in a transaction dated Tuesday, August 17th. The stock was sold at an average price of $47.56, for a total value of $702,889.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.00% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Eagle Bay Advisors LLC purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at approximately $45,000. O Shaughnessy Asset Management LLC purchased a new position in Protagonist Therapeutics during the first quarter valued at $57,000. E Fund Management Co. Ltd. bought a new stake in shares of Protagonist Therapeutics in the 1st quarter worth $82,000. Royal Bank of Canada increased its holdings in shares of Protagonist Therapeutics by 179.3% in the 1st quarter. Royal Bank of Canada now owns 3,324 shares of the company’s stock worth $86,000 after purchasing an additional 2,134 shares in the last quarter. Finally, FORA Capital LLC bought a new stake in shares of Protagonist Therapeutics in the second quarter worth $123,000.

Shares of NASDAQ PTGX traded up $0.41 during trading hours on Wednesday, hitting $19.22. The company had a trading volume of 45,438 shares, compared to its average volume of 589,845. The firm’s 50 day moving average is $44.05 and its 200-day moving average is $37.52. Protagonist Therapeutics has a 1-year low of $12.80 and a 1-year high of $50.54. The stock has a market capitalization of $913.93 million, a P/E ratio of -9.80 and a beta of 1.56.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Featured Article: The limitations of an equal weight rating

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.